BACKGROUND: The relationship between Helicobacter pylori infection and its treatment and gastro-oesophageal reflux disease (GERD) is controversial. AIMS: To establish if H. pylori infection is associated with the presence of GERD and if anti-H. pylori treatment leads to de novo GERD or rebound/exacerbation of GERD. METHODS: A search of MEDLINE and EMBASE databases was made. Pooled odds ratios (OR) were calculated for de novo GERD and rebound/exacerbated GERD after anti-H. pylori therapy in case-control studies and in therapeutic trials. RESULTS: Fourteen case-control studies and 10 clinical trials were included. Among case-control studies, pooled OR for the association between H. pylori negative status and GERD was 1.34 [95% confidence interval (CI) 1.15-1.55]. Among therapeutic trials, pooled OR for the association anti-H. pylori therapy - GERD was 2.54 (95% CI 1.92-3.37). The OR for de novo GERD was 3.25 (95% CI 2.09-5.33), and for rebound/exacerbated GERD was 2.39 (95% CI 1.75-3.34). Associations were higher among Asian studies than among North American and European studies. CONCLUSIONS: This meta-analysis shows significant association between absence of H. pylori infection and GERD symptoms, and a positive association between anti-H. pylori therapy and occurrence of both de novo and rebound/exacerbated GERD. The significance of these associations appears to have been inflated by the effect of single trials and by geographical variations.
BACKGROUND: The relationship between Helicobacter pyloriinfection and its treatment and gastro-oesophageal reflux disease (GERD) is controversial. AIMS: To establish if H. pyloriinfection is associated with the presence of GERD and if anti-H. pylori treatment leads to de novo GERD or rebound/exacerbation of GERD. METHODS: A search of MEDLINE and EMBASE databases was made. Pooled odds ratios (OR) were calculated for de novo GERD and rebound/exacerbated GERD after anti-H. pylori therapy in case-control studies and in therapeutic trials. RESULTS: Fourteen case-control studies and 10 clinical trials were included. Among case-control studies, pooled OR for the association between H. pylori negative status and GERD was 1.34 [95% confidence interval (CI) 1.15-1.55]. Among therapeutic trials, pooled OR for the association anti-H. pylori therapy - GERD was 2.54 (95% CI 1.92-3.37). The OR for de novo GERD was 3.25 (95% CI 2.09-5.33), and for rebound/exacerbated GERD was 2.39 (95% CI 1.75-3.34). Associations were higher among Asian studies than among North American and European studies. CONCLUSIONS: This meta-analysis shows significant association between absence of H. pyloriinfection and GERD symptoms, and a positive association between anti-H. pylori therapy and occurrence of both de novo and rebound/exacerbated GERD. The significance of these associations appears to have been inflated by the effect of single trials and by geographical variations.
Authors: Lori A Fischbach; David Y Graham; Jennifer R Kramer; Massimo Rugge; Gordana Verstovsek; Paola Parente; Abeer Alsarraj; Stephanie Fitzgerald; Yasser Shaib; Neena S Abraham; Anna Kolpachi; Swapna Gupta; Marcelo F Vela; Maria Velez; Rhonda Cole; Bhupinderjit Anand; Hashem B El Serag Journal: Am J Gastroenterol Date: 2014-01-14 Impact factor: 10.864
Authors: Felipe Mazzoleni; Luiz Edmundo Mazzoleni; Carlos Fernando de Magalhães Francesconi; Guilherme Becker Sander; Pâmela Schitz Von Reisswitz; Tobias Cancian Milbradt; Rafael da Veiga Chaves Picon; Diego Mendonça Uchoa; Laura Renata De Bona; Huander Felipe Andreolla; Helenice Pankowski Breyer; Ronaldo Spinato Torresini; Eduardo André Ott; André Castagna Wortmann; Alexandro de Lucena Theil; Jonathas Stifft; Raquel Petrucci Zenker; Candice Franke Krumel; Matheus Truccolo Michalczuk; Alexandre De Araujo; Ane Paula Canevese; Nadja Volpato; Cristiano André da Silva; Pedro Guilherme Schaefer; Natacha Fleck Titton; Larisse Longo; Maria Isabel Edelweiss; Daniel Simon; Nicholas Joseph Talley Journal: Int J Obes (Lond) Date: 2019-06-13 Impact factor: 5.095
Authors: D A Corley; A Kubo; T R Levin; G Block; L Habel; W Zhao; P Leighton; G Rumore; C Quesenberry; P Buffler; J Parsonnet Journal: Gut Date: 2007-09-25 Impact factor: 23.059